The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence
Abstract
Summary: Malignant conditions are frequently associated with a hypercoaguable state, with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation cascade. Heparin and, its pharmacokinetically improved versions, low-molecular-weight heparins (LMWH) are effective in the prevention and treatment of thromboembolic events in cancer patients. There are several lines of preclinical evidence suggesting potential benefits of LMWH in hypercoagulation and thrombosis as well as in various processes involved in tumour growth and metastasis.Tinzaparin is a LMWH produced by controlled enzymatic depolymerisation of unfractionated heparin. The efficacy of tinzaparin has been documented in several clinical trials across various conditions and in special patient populations.The main objective of this review is to present the existing knowledge on the preclinical anti-cancer properties of tinzaparin and other LMWH.The evidence for tinzaparin, as well as other LMWH, regarding interference with cancer-induced hypercoagulation, cancer cell proliferation, degradation of extra-cellular matrix, angiogenesis, selectin-mediated binding of platelet and cancer cells, chemokine signalling, tumour progression, and metastasis are reviewed. Certain clinical trials suggest improved survival of cancer patients with deep venous thrombosis treated with LMWH versus unfractionated heparin and when added to the promising preclinical anti-cancer properties of LMWH this warrants further investigations in prospective, randomised, controlled clinical trials in cancer patients.The benefits of LMWH in cancer might at least in part, be independent from its anti-coagulant activities, but may still be partially dependent on its anti-coagulant activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Daskalopoulos, M. E., Daskalopoulou, S. S., Tzortzis, E., Sfiridis, P., Nikolaou, A., Dimitroulis, D., Kakissis, I., & Liapis, C. D. (2005) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2004.02.029 · Cited by 94
Cited by
Contribution of platelets to tumour metastasis
Gay, L. J., & Felding-Habermann, B. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3004 · Cited by 1,645
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
A conduit to metastasis: circulating tumor cell biology
Micalizzi, D. S., Maheswaran, S., & Haber, D. A. (2017) · Genes & Development · doi:10.1101/gad.305805.117 · Cited by 446
Debele, T. A., Mekuria, S. L., & Tsai, H.-C. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.05.121 · Cited by 317
Heparin: Past, Present, and Future
Oduah, E., Linhardt, R., & Sharfstein, S. (2016) · Pharmaceuticals · doi:10.3390/ph9030038 · Cited by 281
Metadata
- Authors
- Petersen, L., & Mousa, S.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009
- Volume
- 102
- Issue
- 08
- Pages
- 258-267
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2069565722
- Cited by
- 165
- References
- 3
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence. https://app.cochat.ai/papers/10.1160/th08-12-0832
- The paper
- Petersen, L., & Mousa, S. (2009). Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence. Thrombosis and Haemostasis. https://doi.org/10.1160/th08-12-0832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.